Martin Dow Receives DRAP License for Clinical Chemistry Reagents Re-filling and Labelling

Martin Dow, a leading name in Pakistan’s pharmaceutical and healthcare sector, has achieved a significant regulatory milestone by securing an establishment license from the Drug Regulatory Authority of Pakistan (DRAP). The license authorizes the company to re-fill and label clinical chemistry reagents, a critical component in diagnostic testing and laboratory medicine.

Strengthening Pakistan’s Diagnostic Infrastructure

This approval marks a strategic expansion of Martin Dow’s capabilities in the medical diagnostics space. Clinical chemistry reagents are essential for analyzing blood and other bodily fluids, aiding in the diagnosis of conditions ranging from diabetes to liver disorders. By localizing the re-filling and labelling process, Martin Dow aims to enhance supply chain efficiency and reduce dependency on imports.

DRAP’s Role in Ensuring Quality and Compliance

The establishment license reflects Martin Dow’s adherence to DRAP’s stringent regulatory standards. It ensures that the company’s operations meet national benchmarks for safety, quality, and traceability—key factors in maintaining public health and trust in medical products.

A Step Toward Pharmaceutical Innovation and Growth

Martin Dow’s entry into reagent re-filling and labelling aligns with Pakistan’s broader goals of strengthening domestic pharmaceutical manufacturing. The move supports innovation, job creation, and improved access to high-quality diagnostic tools across hospitals and laboratories nationwide.

Commitment to Healthcare Excellence

With this license, Martin Dow reinforces its commitment to advancing healthcare solutions that meet international standards. The company continues to invest in infrastructure, technology, and talent to support Pakistan’s evolving medical needs.